Humacyte, Inc. develops and produces human tissues for treating various diseases across different therapeutic areas. They use their proprietary and scientific technology platform for creating human acellular vessels that can be easily implanted without inducing immune rejection or foreign body response. The company is working on a range of HAVs for the vascular repair market, including peripheral arterial disease and coronary artery bypass grafting, and also developing their HAVs for pediatric heart surgery and cellular therapy delivery.